Todos Medical Ltd. TOMDF
We take great care to ensure that the data presented and summarized in this overview for TODOS MEDICAL LTD. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TOMDF
View allLatest Institutional Activity in TOMDF
Top Purchases
Top Sells
About TOMDF
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
Insider Transactions at TOMDF
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 28
2023
|
Gerald Commissiong CEO and Director |
BUY
Open market or private purchase
|
Direct |
5,000,000
+41.47%
|
-
|
Aug 24
2022
|
Gerald Commissiong CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,000,000
+32.77%
|
$0
$0.03 P/Share
|
Jun 30
2021
|
Gerald Commissiong CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,051,480
+50.0%
|
$0
$0.03 P/Share
|
Apr 05
2021
|
Strategic Investment Holdings, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,873,564
-3.04%
|
$0
$0.08 P/Share
|
Apr 01
2021
|
Strategic Investment Holdings, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
448,300
-0.23%
|
$0
$0.06 P/Share
|
Mar 31
2021
|
Strategic Investment Holdings, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
350,000
-0.24%
|
$0
$0.05 P/Share
|
Jul 07
2020
|
Strategic Investment Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
18,608,113
+27.64%
|
$0
$0.08 P/Share
|
Apr 01
2020
|
Strategic Investment Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
13,008,976
+30.18%
|
$0
$0.08 P/Share
|
Jan 21
2020
|
Strategic Investment Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
17,091,096
+50.0%
|
$0
$0.06 P/Share
|